The latest news from the global pharmaceutical industry. Below you will find news and information to keep you up-to-date with what is happening in your industry. Coverage includes regulatory approvals, recall announcements, mergers and acquisitions, personnel news and appointments, new facility and facility expansion updates, collaborations and agreements, and financial updates.
Wednesday, October 04, 2017
Viking Therapeutics announced positive top-line results from a 25-week proof-of-concept study of VK0214 in an in vivo model of X-linked ...
read more
Wednesday, October 04, 2017
Adynxx announced completion of enrollment in a Phase 2 study of its lead product candidate, brivoligide, for reducing acute pain and preventing ...
read more
Thursday, October 05, 2017
Neurocrine Biosciences announced the FDA has approved an 80 mg INGREZZA capsule strength to be used for the treatment of adults with TD.
read more
Thursday, October 05, 2017
In a recent clinical trial, a gene therapy to treat cerebral adrenoleukodystrophy effectively stabilized the disease's progression in 88 percent of ...
read more
Thursday, October 05, 2017
The first patients have now enrolled in AIRWISE, the world’s largest ever pragmatic clinical trial in COPD to study how commonly prescribed medicines ...
read more
Kadmon announced the FDA has granted orphan drug designation to KD025 for the treatment of chronic graft-versus-host disease.
read more
Therapix Biosciences has entered into an exclusive agreement with Catalent Pharma Solutions for the formulation, development and clinical ...
read more
Cantargia AB announced that the United States Patent and Trademark Office has granted the company's patent application directed to the product ...
read more
The FDA awarded 15 new clinical trial research grants totaling more than $22 million to boost development of products for patients with rare diseases.
read more
Tuesday, October 10, 2017
Mundipharma EDO GmbH has begun a U.S. Phase 1/2 clinical study for tinostamustine (EDO-S101) in patients with advanced solid tumors.
read more
Tuesday, October 10, 2017
Eli Lilly announced that its Phase 3 JUNIPER study evaluating Verzenio as monotherapy in KRAS-mutated, advanced NSCLC did not meet its primary ...
read more
Tuesday, October 10, 2017
The National Multiple Sclerosis Society has committed nearly $14 million to support 40 new MS research projects.
read more
Tuesday, October 10, 2017
Abide announced initiation of dosing in a Phase 1b study to evaluate the effects of ABX-1431.
read more
Thursday, October 12, 2017
Janssen Research & Development
Janssen has submitted a NDA to the FDA for apalutamide.
read more
Thursday, October 12, 2017
Upsher-Smith Laboratories announced the launch of Exemestane Tablets, 25 mg.
read more